alectinib + atezolizumab + entrectinib + divarasib

**Alectinib + atezolizumab + entrectinib + divarasib** denotes a four-agent anticancer treatment concept comprising three targeted small-molecule kinase inhibitors and the anti-PD-L1 monoclonal antibody atezolizumab. Alectinib inhibits ALK and RET; entrectinib inhibits TRKA, TRKB, TRKC, ROS1, and ALK; divarasib is an irreversible, mutation-selective KRAS G12C inhibitor; and atezolizumab blocks PD-L1-mediated immune checkpoint signaling. No public source was identified that establishes this exact four-drug combination as a defined co-formulated product or a specific clinical regimen. Roche platform trials have listed these medicines as separate biomarker-directed interventions or cohort options rather than as one simultaneous four-drug regimen.